Stockwinners Market Radar for February 24, 2025 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:34 EST Marriott CFO sells $4.03M in common stock - In a regulatory filing, Marriott disclosed that its CFO Kathleen Oberg sold 14.5K shares of common stock on February 21st in a total transaction size of $4.03M.

20:32 EST Roblox CFO sells $1.3M in common stock - In a regulatory filing, Roblox disclosed that its CFO Michael Guthrie sold 21.6K shares of common stock on February 20th in a total transaction size of $1.3M.

20:01 EST Cathie Wood's ARK Investment bought 108.8K shares of Iridium today

18:24 EST Cisco exec Subaiya sells 8,973 common shares - In a regulatory filing, Cisco executive VP of operations Thimaya Subaiya disclosed the sale of 8,973 common shares of the company on February 20 at a price of $64.5222 per share.

17:34 EST Zoom Communications says virtual agent will soon expand reasoning ability - Says uniquely positioned to succeed in agentic AI. Says experiencing ongoing macro challenges and uncertainties. Sees Q1 deferred revenue up 4%-5%. Says strategy is to leverage AI. Says guidance assumes enterprise will be the dominant growth driver. Says seen progress in contact center and Workvivo. Comments and guidance taken from Q4 earnings conference call.

17:15 EST Western Digital enters separation pact with Sandisk - The company states in an 8K filing: "On February 21, 2025, Western Digital Corporation entered into definitive agreements with Sandisk Corporation a then-wholly owned subsidiary of the Company. The definitive agreements were entered into in connection with the Company's previously announced plan to separate its flash business from its remaining hard disk drive business, pursuant to a spin-off transaction. The definitive agreements entered into between the Company and Sandisk in connection with the Spin-Off set forth the terms and conditions of the Spin-Off and provide for a framework for the Company's relationship with Sandisk following the Spin-Off, including with respect to the allocation between the Company's and Sandisk's assets, employees, liabilities and obligations attributable to periods prior to, at and after the Spin-Off. These agreements include the Separation and Distribution Agreement, which contains certain key provisions related to the Spin-Off, as well as a Transition Services Agreement, a Tax Matters Agreement, an Employee Matters Agreement, an Intellectual Property Cross-License Agreement, a Transitional Trademark License Agreement, and a Stockholder and Registration Rights Agreement. On February 21, 2025, the Company and Sandisk entered into a Separation and Distribution Agreement that sets forth, among other things, the agreement between the Company and Sandisk regarding the principal transactions necessary to separate Sandisk from the Company and effect the Spin-Off. It also sets forth other agreements that govern certain aspects of the Company's relationship with Sandisk after the completion of the Spin-Off. A summary of certain important terms and conditions of the Separation and Distribution Agreement can be found in the section entitled "Certain Relationships and Related Party Transactions-Material Agreements with WDC-The Separation and Distribution Agreement" in Sandisk's Information Statement, which is included as Exhibit 99.1 to the Company's Current Report on Form 8-K that was filed with the U.S. Securities and Exchange Commission on February 3, 2025. Such summary is incorporated into this Item 1.01 by reference as if restated in full."

17:10 EST Viper Energy sees 1Q production 30,000 - 31,000 Bo/d - As previously announced, on January 30 entered into a definitive purchase and sale agreement to acquire all of the equity interests of certain mineral and royalty interest owning subsidiaries of Diamondback in exchange for $1.0 billion of cash and approximately 69.63 million limited liability company membership interests of Viper Energy Partners along with an accompanying equal amount of Class B common stock of the Company, subject to customary closing adjustments ; expected to close in the second quarter of 2025, subject to the approval by Viper's stockholders and clearance of other typical closing conditions..Initiating average daily production guidance for Q1 2025 of 30,000 to 31,000 bo/d or 54,000 to 56,000 boe/d...

17:09 EST Coterra Energy sees 2025 CapEx $2.1B-$2.4B - Permian drilling and completion capital expenditures are estimated to be approximately $70M lower, driven by improved services costs and acquisition synergies. Marcellus drilling and completion capital expenditures are estimated to be approximately $50M higher than expected in November as activity restarts in the basin early in Q2. Anadarko capital expenditures are expected to be relatively consistent. 2025 production guidance is unchanged at the midpoint from the 2025 pro forma framework announced last November. 2025 total BOE production is expected to be up approximately 9% year-over-year at the mid-point, with oil volumes up approximately 47%, and natural gas volumes relatively flat to 2024 levels. 2025 guidance includes the impact of the recent acquisitions from the closings in late January. Organic 2025 annual oil and BOE growth for Coterra's legacy assets, excluding the recently closed acquisitions, is estimated to be greater than 5% for oil and 0 to 5% for BOE.

16:53 EST Safe Bulkers announces 3M share repurchase authorization - Safe Bulkers announced that it has authorized a program under which it may from time to time in the future purchase up to 3,000,000 shares of the Company's common stock. If the maximum number of shares of the Company's common stock are purchased pursuant to the aforementioned program, it would represent approximately 2.8% of the shares of the Company's common stock outstanding and 5.4% of its public float. The program supersedes any prior repurchase program of the Company. The program does not obligate the Company to purchase shares of the Company's common stock and the program may be modified or terminated at any time without prior notice. Any such purchases will be made in the open market in compliance with applicable laws and regulations, and that purchases on the open market will be conducted within the safe harbor provisions of Regulation 10b-18 under the Securities Exchange Act of 1934, as amended. The purchases will be funded using the Company's existing cash resources.

16:51 EST Terns Pharmaceuticals appoints Andrew Gengos as CFO - Terns Pharmaceuticals announced the appointment of Andrew Gengos as chief financial officer, effective immediately. "We are delighted to have Andrew join the Terns' team as our new chief financial officer, confident his extensive experience and proven track record of financial leadership will be instrumental in driving our growth. We look forward to Andrew's contributions as we continue to advance our mission to transform patients' lives through the development of new medicines that have a valuable, enduring impact on human health," said Amy Burroughs, chief executive officer of Terns. "I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards compelling clinical readouts later this year," said Mr. Gengos. "I look forward to working with the talented Terns' leadership team to build on the Company's strong financial foundation and drive continued success in bringing new treatment options to patients battling serious diseases, including oncology and obesity." Mr. Gengos is a seasoned finance and corporate strategy executive with 25 years of experience, successfully leading teams in the life sciences and biotechnology industry.

16:50 EST Trex Company gains 5% to $65.00 after Q4 earnings beat and guidance

16:35 EST TFI International to retain Canadian corporation status - TFI International announced that based on feedback from shareholders received to date, TFI International will remain a Canadian corporation and will not pursue its previously-announced intention to re-domicile from Canada to the United States.

16:32 EST Cleveland-Cliffs sees FY24 capex of about $700M

16:28 EST Hims & Hers falls 19% to $41.61 after Q4 earnings miss and guidance

16:28 EST Triumph Group extends agreement as supplier to BAE Systems - Triumph Group (TGI) announced it has extended its agreement as a strategic supplier to BAE Systems (BAESY) and the U.S. Army in support of the M777 Lightweight Howitzer platform supplying critical spare Primer Feed Mechanism components. Since 2022, Triumph has shipped 2,365 units and have 938 units on order including the more recent award of an additional 525 units.

16:26 EST Myriad Genetics CEO Paul Diaz to depart, Sam Raha to succeed - Myriad Genetics announced that its board has appointed Sam Raha, the company's current COO, as president and CEO and as a member of the board, effective April 30. Raha will replace Paul Diaz, who is stepping down to join private equity firm Cressey & Company as a managing partner. Diaz will continue to serve the company as a consultant to Raha and the board for another year. The company also announced that Mark Verratti, Myriad's current CCO will be promoted to COO concurrent with Raha's appointment. A search for a new CCO is already underway.

16:23 EST Offerpad Solutions reports Q4 Homes Sold: 503 vs. 712 last year

16:21 EST Civitas Resources aims to cut capital investments nearly 5% in 2025 - Civitas Resources announced its 2025 outlook, including a new debt reduction goal for the year, as well as an enhanced asset portfolio and a recent bolt-on transaction in the Permian Basin. The company says that, in 2025, its goals are: Reducing capital investments nearly 5% year-over-year to a range of $1.8 to $1.9 billion;Delivering oil production between 150 and 155 thousand barrels per day ("MBbl/d") on average; Generating free cash flow of approximately $1.1 billion (at $70 WTI), representing a peer-leading free cash flow yield of 22%; Sustaining a strong base dividend of $0.50 per share quarterly (a nearly 4% yield); Reducing year-end 2025 net debt below $4.5 billion, with the majority of free cash flow after the base dividend targeted for debt reduction; Expanding Permian Basin position with a $300 million bolt-on transaction that adds 19,000 net acres and approximately 130 future development locations in the Midland Basin; Executing on new divestment target of $300 million. Civitas President and CEO Chris Doyle said, "Our 2025 outlook is designed to maximize free cash flow, capitalizing on the sustainable efficiencies we have delivered in our first full year of operating in the Permian Basin and our strong track record of execution in the DJ Basin. We are maintaining a disciplined posture in 2025 in the face of market volatility, sustaining year-on-year activity levels, better level-loading investments through the year, and allocating more of our free cash flow to debt reduction. Along with our successful recent inventory capture, these actions are strengthening the durability of the business through the cycle and supporting our free cash flow delivery well into the future."

16:17 EST Apple Hospitality REIT sees FY25 adjusted EBITDAre $447M-$471M - Sees FY25 CapEx $80M-$90M.

16:15 EST Diamondback Energy produced 475.9 MBO/d or 883.4 MBOE/d in Q4 - "For the quarter, Diamondback produced 475.9 MBO/d or 883.4 MBOE/d, above the high end of the guidance range of 470 - 475 MBO/d or 840 - 850 MBOE/d . Well performance continued to impress with strong results in our Sale and Robertson Ranch areas and on the recently acquired TRP acreage in Upton County. Capital expenditures were $933 million, below the low end of our guidance range of $950 million to $1.05 billion. This beat was primarily driven by Midland Basin well costs continuing to move lower, settling below our stated fourth quarter $600 per lateral foot estimate," said the company in its release.

16:08 EST Sonos announces $150M stock repurchase program - Sonos announced that its Board of Directors has authorized a common stock repurchase program of up to $150 million. The $11 million remaining under the company's existing $200 million repurchase program expired upon approval of the new authorization.

16:01 EST Wah Fu Education to integrate DeepSeek - Wah Fu Education announced that it planned to fully access a domestic large language model - DeepSeek, and to officially enter a new era of strategic AI-based education transformation by upgrading the curriculum system.

15:57 EST Origin Bancorp finds material weakness in internal controls - Origin Bancorp disclosed this morning that after discussion with Forvis Mazars, its independent registered accounting firm, it has identified a material weakness in the company's internal controls over financial reporting relating to controls over employees' ability to initiate certain manual transfers between deposit accounts. The company expects to report on this material weakness in greater detail in an amended annual report for the year ended December 31, 2023, which will state that the company's internal controls over financial reporting were not effective as of December 31, 2023. Management concluded Origin's internal controls over financial reporting also were not effective as of March 31, 2024, June 30, 2024, or September 30, 2024. Accordingly, the company plans to file amended quarterly reports. Management believes that the identified material weakness did not impact the company's consolidated financial statements. "The Company and the Audit Committee are committed to maintaining a strong internal control environment. Management implemented new controls and procedures designed to remediate the identified material weakness," Origin added. The stock in afternoon trading is down 1% to $37.97.

15:22 EST Ming Shing Group Holdings Ltd trading halted, volatility trading pause

14:19 EST Global Star Acquisition Inc trading resumes

14:13 EST WTW boosts dividend 5% to 92c per share - WTW announced that its board of directors approved a regular quarterly cash dividend of 92c per common share for the quarter ended December 31, 2024. This represents a 5% increase to the prior quarter's dividend. The dividend is payable on or about April 15 to shareholders of record at the close of business on March 31.

13:48 EST DoorDash to pay $16.75M to settle New York probe into deceptive pay practices - New York Attorney General Letitia James announced a settlement with DoorDash, under which the company has agreed to pay $16.75M to resolve an investigation that examined the company's alleged violations of New York executive law and general business law. According to an Assurance of Discontinuance, the investigation covered DoorDash's practices that were in place from approximately May 2017 through September 2019. In particular, the investigation focused on concerns regarding whether DoorDash misled both consumers of DoorDash, who used its app to order the delivery of food, and the delivery workers who delivered the orders, concerning how DoorDash used tips that consumers designated for the delivery workers. Rather than the tip being provided to these delivery workers on top of the guaranteed pay offered to a delivery worker before accepting a delivery, the "tip" typically subsidized guaranteed pay offered and was not provided to the delivery workers on top of the guaranteed pay amount. Reference Link

12:46 EST BGL reports sale of Shamrock Environmental to Republic Services - Brown Gibbons Lang & Company, an independent investment bank and financial advisory firm, announced the sale of Shamrock Environmental, an industrial waste and wastewater services platform and portfolio company of CenterOak Partners, to Republic Services. BGL's Environmental Infrastructure investment banking team served as a financial advisor to Shamrock in the transaction. The specific terms of the transaction were not disclosed.

12:02 EST China Yuchai rises 14.5% - China Yuchai is up 14.5%, or $2.90 to $22.90.

12:01 EST Solaris Energy Infrastructure falls -9.9% - Solaris Energy Infrastructure is down -9.9%, or -$3.57 to $32.39.

12:00 EST Tuya falls -12.4% - Tuya is down -12.4%, or -51c to $3.56.

11:26 EST McKesson CEO Tyler sells $5.36M of shares - McKesson CEO Brian Tyler disclosed the sale of 8,961 shares at an average price of $597.99 for a total amount of $5.36M. The share sales included 10b5-1 plan transactions. Tyler still owns over 60,600 shares of McKesson. The stock in late morning trading is up 2% to $607.98.

11:04 EST GeneDx announces publication of research from Seqfirst-neo study - GeneDx announced that the American Journal of Human Genetics published peer-reviewed research from the Seqfirst-neo study conducted in partnership with Seattle Children's and the University of Washington. Seqfirst-neo is a pioneering study focused on the application of rGS in NICU settings to improve access to a genetic diagnosis overall and specifically in underserved communities to reduce missed diagnoses and improve clinical outcomes for patients. Seqfirst-neo is the first study to use exclusion, rather than inclusion, criteria for which infants should receive genomic testing in the NICU, setting a new standard of care by enabling neonatologists to more easily identify patients to receive testing, and expanding access to patients who previously would not have been offered testing. Infants were eligible to receive rGS unless their clinical findings were fully explained by birth/physical trauma, complications of prematurity, infection or a pre-existing precise genetic diagnosis. Findings from the study show that applying simple exclusion criteria significantly increase the number of infants in the NICU receiving a diagnosis, shorten the time to diagnosis, and drove more equitable access for diverse populations who otherwise would have not received testing. The findings further prove that expanding access to genetic testing dramatically increases the rate of a PrGD, enhances healthcare equity and reduces missed diagnoses. Seqfirst-neo's findings suggest that at least 60% of Level IV NICU infants should be receiving rGS. With approximately 400,000 newborn admissions annually across 800 U.S. NICUs, tens of thousands of infants with genetic conditions are likely being undiagnosed due to lack of access to testing. Additional findings from the study. The study evaluated 408 infants in the NICU, of whom 59% met eligibility criteria for rGS. Of those eligible, 126 infants were enrolled in the interventional group and received rGS, while others followed current diagnostic workflow protocols. Nearly half of infants in the IG received a precise genetic diagnosis, an unexpectedly high yield despite broad testing criteria, compared to conventional care. The odds of receiving a PrGD was nine times higher in the IG compared to conventional care. 42% of diagnosed infants would have been missed using conventional NICU protocols, highlighting the limitations of current diagnostic approaches and the correlated inequity of care. 24% of diagnosed infants were not suspected of having a genetic condition based on EMR review and would not have been offered testing under standard care protocols. By using simple, broad exclusion criteria, the diagnostic yield and access to testing were comparable across racial groups, with significantly more non-white and Black infants receiving a PrGD than through conventional care, effectively mitigating racial disparities. Access to a PrGD led to a change in clinical management for nearly 97% of diagnosed infants, influencing medical consultations, additional testing, medication adjustments and family health implications.

10:58 EST CPKC says mechanical employees ratify new collective bargaining agreement - Canadian Pacific Kansas City said that Unifor, representing mechanical employees in Canada, has ratified a new four-year collective agreement. Unifor represents approximately 1,200 mechanics, labourers, diesel service attendants and mechanical support staff across Canada.

10:50 EST Skyx Platforms enters collaboration with Cavco Industries - SKYX Platforms (SKYX) will collaborate with Cavco Industries (CVCO) to utilize SKYX's advanced and smart plug & play technologies in Cavco's premium prefabricated homes during the International Builders' Show) SKYX's technologies will be used in Cavco's high-end homes, including their new premium homes Skye View and Bungalow models, in Show Village during the International Builders' Show place in Las Vegas from February 25-27, 2025.

10:29 EST Pfizer names Patrizia Cavazzoni Chief Medical Officer - Pfizer announced that Patrizia Cavazzoni will rejoin the company as Chief Medical Officer. Cavazzoni was most recently Director of the Center for Drug Evaluation and Research at the Food and Drug Administration.

10:13 EST Manchester United to cut 150-200 jobs as part of transformation plan - Manchester United announces that it will "transform its corporate structure as part of a series of additional measures to improve the club's financial sustainability and enhance operational efficiency." The transformation plan aims to return the club to profitability after five consecutive years of losses since 2019. "This will create a more solid financial platform from which the club can invest in men's and women's football success and improved infrastructure," Manchester said in a statement. As part of these measures, the club anticipates that approximately 150-200 jobs may be made redundant, subject to a consultation process with employees. These would be in addition to the 250 roles removed last year. Omar Berrada, Manchester United CEO, said: "We have a responsibility to put Manchester United in the strongest position to win across our men's, women's and academy teams. We are initiating a wide-ranging series of measures which will transform and renew the club. Unfortunately, this means announcing further potential redundancies and we deeply regret the impact on those affected colleagues. However, these hard choices are necessary to put the club back on a stable financial footing. We have lost money for the past five consecutive years. This cannot continue. Our two main priorities as a club are delivering success on the pitch for our fans and improving our facilities. We cannot invest in these objectives if we are continuously losing money."

10:01 EST TriMas wins multi-year global contract with Airbus - TriMas (TRS) announced that TriMas Aerospace's Monogram Aerospace Fasteners, Allfast Fastening Systems and Mac Fasteners brands have been awarded a multi-year global contract with Airbus (EADSY), expanding the company's existing contract scope across all fastener business units and further strengthening TriMas Aerospace's position across the global Airbus supply chain. TriMas Aerospace will be manufacturing the contracted fasteners in its Commerce and City of Industry, California, facilities, as well as its Ottawa, Kansas, manufacturing site.

10:01 EST Oil States rises 13.5% - Oil States is up 13.5%, or 64c to $5.38.

10:00 EST Youdao falls -10.4% - Youdao is down -10.4%, or -$1.07 to $9.19.

10:00 EST Tuya falls -11.7% - Tuya is down -11.7%, or -47c to $3.58.

09:47 EST Oil States rises 9.1% - Oil States is up 9.1%, or 43c to $5.17.

09:47 EST Bridge Investment rises 33.6% - Bridge Investment is up 33.6%, or $2.66 to $10.58.

09:47 EST Fresh Del Monte falls -9.6% - Fresh Del Monte is down -9.6%, or -$2.95 to $27.93.

09:41 EST First Busey appoints Scott Phillips as interim CFO, succeeding Jeffrey Jones - In a regulatory filing on Friday, First Busey said that it entered into a Separation Agreement with Jeffrey D. Jones, the former Executive Vice President, CFO of the company and Busey Bank, confirming the separation of Jones from his employment with the company and its subsidiaries effective February 18, 2025. Jones' separation from the company was not related in any way to, and did not involve any disagreement with respect to, the company's financial reporting or financial condition, operations, or financial policies or practices, including the company's controls, or the pending acquisition of CrossFirst Bankshares, Inc. Effective February 18, the board appointed Scott A. Phillips, CPA, as Interim CFO of the company. Phillips also will serve as the Interim CFO of Busey Bank, the company's principal subsidiary. Phillips,has served as the company's Senior Vice President, Corporate Controller and Principal Accounting Officer since 2023 and as the company's Senior Vice President, Corporate Controller since 2019.

09:40 EST Telix Pharmaceuticals Ltd trading resumes

09:38 EST Yoshiharu Global Co trading resumes

09:36 EST MicroAlgo Inc trading halted, volatility trading pause

09:35 EST Telix Pharmaceuticals Ltd trading halted, volatility trading pause

09:33 EST Capital Bancorp completes conversion of Integrated Financial Holdings - Capital Bancorp had completed the conversion of Integrated Financial Holdings into its operations and systems. This conversion integrates IFH customer accounts into CBNK's products and services. West Town Bank & Trust and Windsor Advantage previously operated as subsidiaries of IFH. In connection with the merger completed on October 1, 2024, West Town Bank & Trust merged with and into Capital Bank and Windsor Advantage became a subsidiary of Capital Bancorp/ CBNK completed the conversion between the close of business on February 21st and reopening on February 24th. IFH customers, including customers of its North Riverside, IL branch, now have access to a wide selection of CBNK products and services. In addition, they can bank at any CBNK location, through digital banking or ATM. In connection with the merger, CBNK also anticipates opening a branch in Raleigh, NC on March 3, 2025.

09:30 EST Blackstone to acquire Safe Harbor from Sun Communities for $5.65B - Blackstone (BX) announced that funds managed by Blackstone Infrastructure have agreed to acquire Safe Harbor Marinas from Sun Communities (SUI) for $5.65B. Safe Harbor owns and operates 138 marinas across the U.S. and Puerto Rico.

09:26 EST Bright Green completes restructuring plan, withdraws from cannabis business - Bright Green announced that on February 24, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement. The highlights of the RSA will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. The Company in its restructuring efforts has entered into an agreement with the DEA to immediately withdraw all Cannabis related renewal applications. This agreement will allow for reinstatement once the Company is satisfied that there is commercial value, and the federal government clarifies a path that will stabilize operations for medical research and possible drug development. Lynn Stockwell, the new CEO and Chairman of the Board of Directors of the Company also sponsors and manages other public corporations that are building a financial war chest to be used for acquisitions of revenue generating, well managed corporations for the platform of onshoring controlled substance production, API and manufacturing back to the U.S. These legal controlled substances have never been produced commercially in the United States. The critical supply is imported from countries where diversion and quality controls are not a priority. Gurvinder Singh will rejoin the Company as General Manager responsible for the EB-5 program administered by Bright Green Regional Center and help direct the Company forward. The Company's planned revenue is from contracts for production of controlled substances and EB-5 investment, the $800,000 investment from applicants seeking a green card administered by the USCIS EB-5 program that could generate significant capital from qualified applicants that seek entry into the United States through legal immigration.

09:22 EST Sun Communities to sell Safe Harbor Marinas business for $5.65B - Sun Communities has entered into a definitive agreement to sell 100% of its interests in the Safe Harbor Marinas business to affiliates of Blackstone Infrastructure. The transaction accelerates Sun's strategic goal of re-focusing on its core MH and RV segments and significantly enhances its leverage profile and financial flexibility. Upon the closing of the transaction, Blackstone will purchase Safe Harbor from the Company for an all-cash purchase price of $5.65 billion, subject to certain post-closing adjustments. The base purchase price represents an approximate 21x multiple on the estimated 2024 Funds From Operations of the Safe Harbor business. The transaction is expected to produce approximately $5.5 billion of pre-tax proceeds after transaction costs, which will strengthen the Company's balance sheet. Proceeds are anticipated to be used to support a combination of debt reduction, distributions to shareholders and reinvestment in the Company's core businesses. Transaction Benefits Re-focuses Business Strategy. Post-transaction, Sun's North America MH and RV portfolio is expected to account for approximately 90% of the Company's Net Operating Income, streamlining its strategic focus as a pure-play MH and RV owner and operator. Enhances Financial and Strategic Flexibility. The transaction, once completed, is expected to meaningfully de-leverage Sun's balance sheet. Initially following the transaction, the Company expects its net debt to trailing 12 months EBITDA, on a pro forma basis, to be reduced from approximately 6.0x to between 2.5x and 3.0x at closing. Reinforces Focus on Durable, Annual Income Streams. The transaction is expected to reduce the Company's exposure to Service, Retail, Dining and Entertainment and other non-annual income streams while positively impacting the Company's financial metrics including its margin profile, overhead efficiency, capital expenditure requirements and revenue-to-cash flow conversion. Realizes Substantial Gain. The transaction is expected to monetize a successful investment, generating strong returns for shareholders, including an estimated book gain of approximately $1.3 billion from Sun's approximately four-year ownership of Safe Harbor. Tax Treatment The Company is actively evaluating its available strategies to maximize efficiency for Sun and its shareholders with respect to gains realized from the transaction, including various tax and distribution options. The Company expects to provide further guidance on the tax implications of the transaction prior to closing. Timing The transaction is subject to customary closing conditions, and the initial closing of the transaction is expected in the second quarter of 2025. Certain properties representing approximately 10% of the total consideration may be transferred and paid for in one or more subsequent closings, subject to receipt of certain third-party approvals.

09:20 EST SharpLink Gaming acquires 10% equity stake in Armchair Enterprises - SharpLink Gaming announced that the Company has acquired a 10% equity stake in U.K.-based Armchair Enterprises, which owns and operates CryptoCasino.com. The acquisition was made for $500,000 in cash, along with a right of first refusal to acquire a controlling interest in Armchair. The company said, "SharpLink's investment in Armchair demonstrates its strategy to become the first Nasdaq-listed company focused on crypto gaming...Launched in October 2024, CryptoCasino.com is an innovative online gaming platform that partners with some of the world's leading gaming studios. It utilizes blockchain technology to provide users with a secure, transparent and engaging next-generation gaming experience. The platform plans to offer over 6,000 online slots and table games, a live dealer casino, a premium sportsbook, an eSports betting hub and a racebook, among other features. CryptoCasino.com accepts a wide range of cryptocurrencies, including Bitcoin, Ethereum, Litecoin and more, catering to various user preferences globally while ensuring enhanced security, transparency and anonymity for players. CryptoCasino.com offers both traditional registration and Web3 connectivity. By connecting instantly with wallets like MetaMask and Trust Wallet, players can easily deposit and withdraw funds within seconds. In addition, CryptoCasino.com serves over one billion unique Telegram users by providing a Telegram Casino integration, which allows anyone to join and start playing with just one click."

09:17 EST American Resources advances feedstock sourcing for ReElement - American Resources announced its strategic focus on sourcing and investing in key commodities to be refined by ReElement Technologies, supporting both defense and commercial markets. Leveraging immediate opportunities, American Resources will concentrate already mined coal waste feedstock containing heavy and light rare earth elements as well as alumina and silicon dioxide. These materials will be aggregated, processed and supplied to ReElement Technologies for final-stage refinement into ultra-pure, commercial-grade products. Additionally, the distributions of the shares of ReElement Technologies Corporation and American Infrastructure Corporation to shareholders of record as of December 31st, 2024, is currently underway through the Company's transfer agent. American Infrastructure common shares will be exchanged for Series A Preferred Stock in CGrowth Capital, which is expecting to rebrand as American Infrastructure Holding Corporation. ReElement is currently the only producer in the United States producing heavy and light rare earth oxides at magnet-grade. ReElement has either signed contracts, term sheets or MOU's with an estimated 70% of the downstream market that is planning operations in the United States. ReElement's technology is the only refining technology that can deploy locally in a scalable manner throughout the United States and the world for various feedstock refining. American Resources has access to over 30,000 acres of controlled land and internal estimates of over 128 million tons of previously extracted waste material in Kentucky, West Virginia and Indiana and is contemplating additional growth in other areas as concentration sites. American Resources is working on commodity sourcing through its partnerships worldwide for other natural-occurring elements that can be refined by ReElement such as antimony, germanium, molybdenum, battery minerals and other rare earth concentrates. American Resources remains an approximately 19% shareholder in ReElement and approximately 9% shareholder in American Infrastructure Corporation.

09:15 EST American Resources advances feedstock sourcing for ReElement Technologies - American Resource announced its strategic focus on sourcing and investing in key commodities to be refined by ReElement Technologies, supporting both defense and commercial markets. Leveraging immediate opportunities, American Resources will concentrate already mined coal waste feedstock containing heavy and light rare earth elements as well as alumina and silicon dioxide. These materials will be aggregated, processed and supplied to ReElement Technologies for final-stage refinement into ultra-pure, commercial-grade products. Mark Jensen, Chairman and CEO of American Resources Corporation and ReElement Technologies, commented "The advancements made by the ReElement technical team are groundbreaking and could not come at a more critical time, given the global shortage of heavy rare earth oxides today. ReElement's technology has successfully demonstrated its ability to economically separate, purify and refine coal waste concentrates - something traditional solvent extraction methods cannot achieve due to the inherent impurity streams. Historically, coal waste or coal-based feedstock have been financial burdens on our government and communities. However, with our advanced technology, we can not only make these materials economically viable but also establish them as a primary source of critical minerals essential for national security. Coal waste feedstock is laden with alumina, silica, zinc and other impurities that make traditional chemical to chemical separation methods inefficient and costly. With ReElement's chromatographic separation methods, these impurities either become negligible or transform into valuable byproducts, enhancing the overall process. With the millions, if not billions, of tons of material already mined and stored around the world, these innovations have the potential to reshape the global resource dynamics. In response, American Resources is now strategically focused on aggregating and processing its own and other sources of mine waste to supply ReElement's refining operations." Additionally, the distributions of the shares of ReElement Technologies Corporation and American Infrastructure Corporation to shareholders of record as of December 31st is currently underway through the Company's transfer agent. American Infrastructure common shares will be exchanged for Series A Preferred Stock in CGrowth Capital, Inc which is expecting to rebrand as American Infrastructure Holding Corporation.

09:13 EST Amdocs announces expansion of eSIM SaaS platform with RCS support - Amdocs announced that its eSIM Cloud platform has reached RCS compliance for Android, accelerating the adoption of advanced messaging capabilities for Android. Amdocs Entitlements Server, part of the Amdocs eSIM Cloud, is now integrated with the Google Configuration Server, enabling advanced messaging capabilities like Rich Communication Services, VoIP, and VoWi-Fi services between devices. Amdocs eSIM Cloud's also supports Google Cloud's Telecom Subscriber Insights-based eSIM activation, subscription transfer, and integration with wearable devices. ACS manages and configures devices on the network, automating firmware updates and security patches.

09:10 EST Collective Audience appoints Sean McCormick to Advisor Collective - Collective Audience has appointed Sean McCormick to its Advisor Collective, a community of strategic advisors who share a commitment to the transformation of the AdTech, MarTech and digital media industries for the benefit of advertisers and publishers. He previously served as VP and head of Digital and Performance Marketing at EXL, a leader in data analytics solutions.

09:06 EST Baker Hughes appoints Ahmed Moghal as CFO - Baker Hughes Company announced that Ahmed Moghal, who currently serves as CFO of the Industrial & Energy Technology business, has been appointed CFO of the Company, effective immediately. In this role, he succeeds Nancy Buese, who, by mutual agreement with the Company, ceased to serve as CFO. With Moghal's appointment, Buese will move to a strategic adviser role and will depart the Company on April 30, 2025.

09:05 EST ZK International Group regains Nasdaq listing compliance - ZK International Group announced that the bid price deficiency concern raised by Nasdaq has been resolved. The company has received written notification from Nasdaq notifying the company that it has regained compliance with the minimum bid price requirement as the company's closing bid price exceeded $1.00 for 10 consecutive business days. On February 14, the Staff notified the company that it has regained compliance with the Rule and the matter is now closed.

09:04 EST Taboola announces exclusive three-year deal with LINE - Taboola announced a new, exclusive three-year deal with LINE, a diverse, global ecosystem that includes a messaging app, lifestyle, fintech, Web3, e-commerce, gaming, entertainment, AI, and more, reaching nearly 200 million monthly active users. This agreement marks Taboola as LINE's first third-party partner for providing a news service in countries where such a service is not yet available. Under the new long-term, highly strategic partnership, LINE Plus, LINE's business arm operating in global markets, will integrate Taboola News to power recommendations and ads globally in new, engaging ways. Taboola News brings recommendations from Taboola's large publisher network directly into offerings from mobile carriers and device manufacturers, including smartphone screens. Taboola and LINE have an existing relationship and began working together in 2021.

09:03 EST Medtronic's BrainSense brain stimulation system approved by FDA for Parkinson's - Medtronic announced FDA approval of BrainSense Adaptive deep brain stimulation - aDBS - and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like Parkinson's, however, deep brain stimulation, or DBS, has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders. Medtronic has enhanced its Percept DBS neurostimulators with BrainSense Adaptive technology, introducing aDBS for people living with Parkinson's. It provides enhanced therapy personalization for symptom control that automatically adjusts. The FDA approval also includes the Medtronic BrainSense Electrode Identifier, which helps reduce patient time spent in clinic to program their DBS settings.

09:02 EST Dillard's introduces Style by Simkins for Antonio Melani - Dillard's announced Style by Simkins for Antonio Melani, now available on dillards.com as well as in stores nationwide. New York City-based content creator and fashion stylist, Natalie Simkins, has created this elegant and comprehensive Spring/Summer collaboration exclusively for Dillard's Antonio Melani customers. Style by Simkins for Antonio Melani showcases a coordinating collection of Spring/Summer dresses and separates in sizes ranging from 0-18 and XS to XL as well as footwear, swimwear and coverups. It is available for a limited time on dillards.com and in Dillard's stores nationwide.

09:01 EST MongoDB acquires Voyage AI, terms not disclosed - MongoDB announced it has acquired Voyage AI, a pioneer in state-of-the-art embedding and reranking models that power next-generation AI applications. Integrating Voyage AI's technology with MongoDB will enable organizations to easily build trustworthy, AI-powered applications by offering highly accurate and relevant information retrieval deeply integrated with operational data. Voyage AI's embedding and reranking models will remain available through voyage.ai, AWS Marketplace, and Azure Marketplace, with further MongoDB integrations launching later this year.

08:59 EST N2OFF, Solterra close agreement to develop 196 MWp battery storage projects - N2OFF announced the closing of a definitive agreement with Solterra Renewable Energy subsidiary, Soltera Brand Services Italy. According to the agreement, the purchased projects relate to 2 Battery Storage systems in Sicily, Italy, each with a capacity of 98MWp/392MWh. The agreement includes the purchase and development of the projects, with a total investment of up to EUR 2.3 million, to be paid in milestones. N2OFF will hold 70% ownership in the projects, further solidifying its entry into the European energy storage market. These projects are part of the broader joint venture between N2OFF and Solterra Renewable Energy, which focuses on solar and energy storage initiatives. The collaboration reflects the companies 'shared vision of advancing renewable energy adoption and addressing the increasing demand for energy storage solutions to enhance grid flexibility. The current 2 BESS projects have already received approval for the connection capacity from Terna, which will be secured simultaneously with the closing of the transaction. The development is currently expected to take 18-24 months for these projects to reach a Ready-to-Build stage.

08:56 EST Consolidated Water's Cayman Water receives water production, supply concession - Consolidated Water reported that its wholly owned subsidiary, Cayman Water Company, has received its new concession from the Cayman Islands government that grants it the continued exclusive rights to produce and supply potable water within its existing service area on Grand Cayman, the largest island of the Cayman Islands. Cayman Water Company operates three sea water reverse osmosis desalination plants on Grand Cayman that produce approximately 4 million gallons per day of potable water for the island's residences and businesses. The company recently reported increased retail water sales due to the continued business and population growth on the island. In 2018, the Cayman Islands enacted changes to its regulatory framework governing water utilities. This new framework requires Cayman Water to first be granted a concession before obtaining or renewing the associated operating license. Cayman Water will next commence negotiations with the Cayman Islands utility regulator, OfReg, to secure the license. The new license is expected to involve a restructuring of the previous operating terms and conditions. Cayman Water's existing operating license that it received in 1990 will remain in force until the new license is issued by OfReg.

08:52 EST MiNK Therapeutics presents allo-iNKTs combination data in 2L gastric cancer - MiNK Therapeutics presented new translational data from its ongoing Phase 2 study of allo-iNKTs, agenT-797, at the American Association for Cancer Research IO Annual Meeting in Los Angeles, California. The study evaluates agenT-797 in combination with botensilimab and balstilimab, in patients with refractory gastroesophageal cancer. Early induction with MiNK's allogeneic iNKT product, agenT-797, drove broad immune activation-a hallmark of potential durable responses. Investigators report significant increase in interferon-gamma levels, along with enhanced tumor infiltration by T cells and antigen-presenting cells signaling robust systemic immune engagement. These biomarkers typically correlate with improved clinical outcomes and a sustained anti-tumor immune response, reinforcing the potential of this combination in solid cancers. The most pronounced immune expansion and strong peripheral memory T-cell activation were seen when agenT-797 was given concurrently with checkpoint inhibitors and before standard chemotherapy. This underscores the critical importance of treatment sequencing, positioning early allo-iNKT induction as a key driver of therapeutic benefit. Allogeneic, Off-the-Shelf Platform: MiNK's scalable manufacturing process generates billions of donor-derived iNKT cells in a single run, yielding thousands of doses for rapid global distribution. This approach reduces logistical hurdles and lowers costs, enabling greater patient access worldwide. Differentiated Pipeline: MiNK's iNKT platform supports expansion into additional hard-to-treat cancers, creating significant opportunities for pipeline breadth, partnerships, and long-term growth.

08:49 EST TruGolf Links to launch hybrid golf concept for franchisees - TruGolf announced it's bringing a fully patented hybrid golf simulator solution to the franchise market. This technology, five years in development, puts simulator technology onto physical golf courses allowing for a new, tech infused way of playing golf. Merging the virtual and physical worlds of golf has been recently popularized by the high-profile TGL giving proof that the golfing world is open to new and different playing formats. The company said, "This groundbreaking product is made possible by TruGolf Links long standing close relationship with Nexus Golf. To further that relationship, Nexus Golf has announced a strategic investment in TruGolf Links. With this breakthrough, regional developers will have access to a next-generation indoor-outdoor golf experience, allowing consumers in their area to engage with the sport in an entirely new way. By merging advanced simulation technology with real-world gameplay, this hybrid solution offers a compelling and immersive alternative to traditional golf, making the sport more accessible, interactive, and engaging for players of all skill levels. It also will change the business equation for golf course operators, expanding operating hours, better leveraging existing infrastructure and creating new revenue streams. Hybrid golf technology will allow for full length golf to be played at night without lighting an entire golf course. Night golf is currently limited to smaller par 3 golf courses...The patented hybrid golf simulator solution will be rolled out across TruGolf Links franchise locations, creating new revenue streams for entrepreneurs while giving golf enthusiasts an exciting, modern way to enjoy the game year-round. We anticipate the first hybrid franchise location to be operational by the end of 2025."

08:46 EST CytoDyn announces survival observations in mTNBC patients - CytoDyn announced survival outcomes among a group of patients with metastatic triple-negative breast cancer treated with leronlimab. Although mTNBC typically has a poor prognosis, observed survival rates at 12, 24, and 36 months after treatment with leronlimab compare favorably with reported life expectancy after treatment with currently approved therapies. In addition, the Company confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease. Following the resolution of the Company's dispute with its former CRO, CytoDyn obtained follow-up records from patients treated with leronlimab during the Company's prior clinical trials in oncology. After confirming these patient outcomes, CytoDyn worked with consultants and key opinion leaders to summarize the findings and submit an abstract to the European Society for Medical Oncology Breast Cancer meeting taking place in Munich, Germany, from May 14 to 17, 2025. Based on these survival observations, the Company has initiated two pre-clinical studies in mTNBC that will evaluate possible treatment synergies between leronlimab, an antibody-drug complex treatment, and an immune checkpoint inhibitor. The Company will also continue to perform follow-up testing on the group of mTNBC survivors who currently identify as having no evidence of ongoing disease.

08:44 EST Myriad Genetics partners with PATHOMIQ for AI tech platform - Myriad Genetics and PATHOMIQ entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ's AI technology platform for prostate cancer, in the United States. Machine learning and AI-enabled diagnostics are transforming the way clinicians approach cancer patient care. Adding PATHOMIQ_PRAD to Myriad's Oncology Solutions allows Myriad to provide urologist and radiation oncologists with molecular and AI-powered testing solutions to inform decisions both before treatment at the time of biopsy for active surveillance and following surgery or radiation treatment. This complements Myriad's existing offerings of combined germline and comprehensive tumor profiling as recommended by NCCN guidelines for prostate cancer care. In addition to expanding Myriad's prostate cancer testing portfolio to include post-surgical treatment testing solutions, the collaboration with PATHOMIQ is also envisioned to accelerate the timelines for meeting Simon level 1 evidence for both Prolaris and PATHOMIQ_PRAD. While the current PATHOMIQ_PRAD model is specific for use in patients with prostate cancer after surgery, the underlying foundational model provides opportunities for applications in virtually all solid tumor cancers that are diagnosed through a biopsy with H&E staining. Myriad intends to commercially launch its first AI-driven prostate cancer clinical test later this year.

08:43 EST Yerbae Brands, Safety Shot to join FORCE Family Webinar - Yerbae Brands and Safety Shot announced that their respective CEOs, Todd Gibson and Jarrett Boon, will join the FORCE Family Webinar to provide insights on how Yerbae and Safety Shot plans to disrupt the functional beverage market. The webinar is scheduled for Tuesday, February 25, at 12:00 PM ET / 9:00 AM PT. On January 8, 2025, Yerbae and Safety Shot announced the execution of a definitive arrangement agreement dated January 7, 2025, marking a major step toward redefining the landscape of healthy and functional beverages. This proposed strategic acquisition aims to bring together Safety Shot's groundbreaking wellness solutions with Yerbae's popular line of plant-based energy drinks.

08:43 EST Bristol Myers CEO bought $110K in common stock - In a regulatory filing on Friday night, Bristol Myers disclosed that its CEO Christopher Boerner bought 2K shares of common stock on February 20th in a total transaction size of $110.1K.

08:42 EST Canacol Energy sees FY25 capital budget $143M-$160M - Canacol Energy provided its capital and gas sales guidance for 2025. The corporation announces that its 2025 capital budget is between $143M-$160M. Forecast average realized contractual gas sales and oil sales for 2025, which include downtime, are anticipated to range between 146 and 159 million cubic feet equivalent per day. The corporation's firm 2025 take-or-pay natural gas contracts average 111 MMcfpd, net of contractual downtime. The average wellhead natural gas sales price, net of transportation costs, is expected to range between $7.33/Mcf and $7.65/Mcf on average.

08:40 EST Canacol Energy sees FY25 capital budge $143M-$160M - Canacol Energy provided its capital and gas sales guidance for 2025. The Corporation announces that its 2025 capital budget is between $143 million and $160 million. Forecast average realized contractual gas sales and oil sales for 2025, which include downtime, are anticipated to range between 146 and 159 million cubic feet equivalent per day. The Corporation's firm 2025 take-or-pay natural gas contracts average 111 MMcfpd, net of contractual downtime. The average wellhead natural gas sales price, net of transportation costs, is expected to range between $7.33/Mcf and $7.65/Mcf on average. Corporate Plan for 2025 Charle Gamba, President and CEO of Canacol, stated: "In 2025 the Corporation is focused on i) maintaining and growing our reserve base and production from our core assets in the Lower Magdalena Valley Basin, targeting the full use of existing transportation infrastructure; ii) exploring higher impact gas exploration opportunities in the Lower and Middle Magdalena Valley Basin; iii) laying the groundwork to be able to commence operations in Bolivia in 2026 and iv) continue our commitment to our ESG strategy". For 2025, the Corporation is focused on the following specific objectives: In line with maintaining and growing our reserves and production in our core gas assets in the Lower Magdalena Valley Basin we plan to optimize our production and increase reserves by drilling up to 11 exploration and 3 development wells, install new compression and processing facilities as required, and workover operations of producing wells in our key gas fields. These development and exploration activities are planned to support our robust EBITDA generation and allow us to capitalize on strong gas market dynamics in 2025. The development wells include the Clarinete-11, Siku-2 and Lulo-3 wells, all of which have already been successfully drilled and brought on production. The exploration drilling plan includes 10 gas exploration wells in the LMV and one gas and condensate exploration well in the Middle Magdalena Valley. Notable exploration wells in the LMV include continuing operations at Natilla-2 ST2, which encountered approximately 550 ft TVD gross section of interbedded sandstone and shales within the Porquero with good reservoir quality as indicated by sonic and resistivity logs collected while drilling. Formation pressures across this section of the Porquero ranged from 12,500 - 13,500 psi based on the PWD tool, indicating gas at very high pressure, and very high mud weights of up to 18.8 pounds per gallon while drilling were required to prevent the influx of gas into the wellbore. Despite the heavy mud weights used while drilling through this section of the Porquero, total measured gas confirmed that the sandstones are gas charged. Other notable exploration wells include the Ramsay-1 which is targeting a large 4 way closure within the CDO sandstone reservoir located close to the Nelson field which we plan to spud in the second quarter, and a group consisting of 3 exploration wells targeting 3 separate prospects within the CDO sandstone reservoir located close to our Nispero gas field, the first of which we plan to also spud in the early second quarter. While a discovery at Natilla will take approximately 9 months to bring on production due to the need to build a 15 kilometer flow line, Ramsay, Zamia, Borbon, and Monstera can be quickly brought on production if successful due to their proximity to existing flowlines. The remaining 5 exploration wells are targeting smaller structures located close to existing infrastructure that can be commercialized rapidly if successful. Over the last several years the Corporation has assembled a significant acreage position in the MMV, and this year we plan to drill the Valiente prospect targeting a large shallow structure located approximately 5 kilometers to the south and up dip of the Opon gas field discovered in 1965 by Cities Services and later developed by Amoco in 1997. The productive sandstone reservoirs within the Tertiary La Paz Formation at Opon reached a production peak of approximately 104 MMcfpd of gas and 3,790 barrels of condensate per day in 1998, and produced a total of 54 billion cubic feet of gas and 1.2 million barrels of condensate. Valiente-1 is planned to spud in early fourth quarter and will target the same productive sandstones of the La Paz Formation that were productive at Opon, but at considerably shallower depths. The Corporation is also continuing its efforts with respect to the Pola exploration project located in the MMV. Pola is a large prospect targeting gas within Cretaceous aged reservoirs at depths of close to 17,000 feet. Given the relatively high cost of the well, the Corporation is currently evaluating its options with respect to how to proceed with the project. In Bolivia the Corporation is awaiting ratification and formalization by congress of three exploration contracts and one field redevelopment contract in order to establish the effective date of all four contracts. The Corporation is currently preparing to apply for the environmental permit for Tita, along with formulating development plans, in order to commence field reactivation activities in 2026.

08:37 EST Foresight Autonomous integrates Nvidia Jetson Orin into perception tech - Foresight Autonomous announces the integration of NVIDIA Jetson Orin computing platforms into its perception technologies. The collaboration leverages NVIDIA Jetson Orin Nano and NVIDIA Jetson AGX Orin platforms to enhance the capabilities of Foresight's 3D perception systems across various industries, with focus on autonomous drone and unmanned aerial vehicles. The NVIDIA Jetson Orin platform provides Foresight's vision systems with state-of-the-art computing power tailored to the unique requirements of autonomous drones and UAVs. The NVIDIA Jetson Orin Nano is optimized for compact, lightweight drones and UAVs, offering robust artificial intelligence performance and energy efficiency while minimizing weight and size. These platforms reduce power consumption while maintaining high performance, making them ideal for drones in large-scale or remote-area applications. For higher-performance needs, the NVIDIA Jetson AGX Orin delivers up to 275 trillion operations per second, enabling real-time data processing, advanced obstacle detection, and precise terrain mapping in complex and dynamic environments.

08:36 EST Mirum Pharmaceuticals announces FDA approval for Ctexli tablets - Mirum Pharmaceuticals announced that the FDA has approved Ctexli tablets, a bile acid, for the treatment of adults with cerebrotendinous xanthomatosis. Ctexli is the first and only treatment approved for this rare, progressive and debilitating disease.

08:33 EST Innovex signs frame agreement with SLB OneSubsea - Innovex announced the signing of a strategic frame agreement with SLB OneSubsea, for the supply of subsea wellhead systems. The company said this agreement establishes a standard framework for enhanced collaboration, paving the way for faster development of future business opportunities, strengthening the long-standing relationship between OneSubsea and Dril-Quip.

08:32 EST Former Statera CEO Michael Handley named Tivic Biopharma president - Tivic Health Systems announced that Michael K. Handley, formerly Chief Executive Officer, President and Chairman of Statera Biopharma has joined Tivic Health as the President of Tivic Biopharma, a newly formed division of Tivic Health. Additionally, he will assume the role of Chief Operating Officer of Tivic Health and will work closely with the CEO and other leadership team members to develop and operationalize company-wide strategies. "Mike brings to Tivic a rare blend of device and pharmaceutical background, as well as proven operational, business and scientific experience that sets Tivic up for a smooth and successful expansion into drug development," stated Tivic Health Chief Executive Officer, Jennifer Ernst. "With our recent licensing of the late-stage TLR5 agonist, Entolimod, from Statera Biopharma, and Mike's deep experience in immunology and biotech, we believe that he is the ideal leader to establish Tivic's biopharmaceutical capabilities and advance our therapeutics pipeline. In tandem, we continue to pursue the development and exciting promise of our non-invasive bioelectronic vagus nerve stimulation, creating a portfolio of device and drug therapeutics from which to build shareholder value," added Ernst.

08:31 EST Foxo executes non-binding agreement two acquire two Florida facilities - FOXO Technologies has executed a non-binding acquisition agreement for two assisted living facilities in Florida. One facility has 129 units, and the second facility has 137 units. The purchase price for each facility is expected to be $30 million, a portion of which is milestone-based. The parties aim to complete definitive agreements withing 60 days, Closing is expected to occur between 60 and 120 days after completion of definitive agreements and is subject to a number of closing conditions, including satisfactory due diligence and financing.

08:29 EST Douglas Dynamics appoints Chris Bernauer as president, Work Truck Attachments - Douglas Dynamics announced the appointment of Chris Bernauer as President of Work Truck Attachments, effective February 28, 2025. Most recently, he served as President & CEO of Temperature Systems. Based in Milwaukee and reporting to COO Mark Van Genderen, Bernauer will manage all facets of Work Truck Attachments, including strategy, operations, and new product development. Bernauer takes over the President of Work Truck Attachments role from Mark Van Genderen.

08:26 EST Arcutis Biotherapeutics announces publication of data from INTEGUMENT-PED trial - Arcutis Biotherapeutics announced that Pediatric Dermatology published online positive results from INTEGUMENT-PED, the pivotal phase 3 randomized vehicle-controlled trial evaluating the efficacy and safety of ZORYVE cream 0.05%as a once-daily, steroid-free treatment for mild to moderate atopic dermatitis in children 2 to 5 years old. The study found that treatment with investigational once-daily ZORYVE cream 0.05% resulted in significant improvements across multiple efficacy endpoints, including achieving a statistically significant improvement in the primary efficacy endpoint of IGA Success, as well as statistically significant improvements in additional endpoints, including 75% improvement in the Eczema Area and Severity Index and Worst Itch Numeric Scale at Week 4. The data also show improvement in itch was observed as early as 24 hours after first application. INTEGUMENT-PED is a Phase 3, parallel group, double blind, vehicle-controlled trial in which roflumilast cream 0.05% or vehicle was applied once daily for four weeks to children 2 to 5 years of age with mild to moderate AD. A total of 652 children were enrolled in the study, with a mean Body Surface Area of 22% overall, and a range from 3% to 82%. As previously reported, at Week 4, 25.4% of children treated with ZORYVE cream 0.05% achieved vIGA-AD Success, defined as a validated Investigator Global Assessment - Atopic Dermatitis score of 'Clear' or 'Almost Clear' plus a 2-grade improvement from baseline, compared to 10.7% of children treated with vehicle, with significant improvements seen as early as Week 1. Other key findings included: Rapid improvement in itch was observed in children treated with ZORYVE cream within 24 hours of the first application, as measured by the change from baseline in daily WI-NRS scores, compared with vehicle. 35.3% of children treated with ZORYVE cream achieved a four-point reduction in WI-NRS at Week 4 vs. 18.0% for vehicle-treated subjects. 39.4% of children treated with ZORYVE cream achieved a 75% improvement in EASI score at Week 4 compared to 20.6% treated with vehicle. Significant improvements based on EASI-75 were observed with ZORYVE cream compared to vehicle as early as Week 1. 35.4% of children treated with ZORYVE cream 0.05% achieved a vIGA-AD score of 'clear' or 'almost clear' at Week 4, with significant improvements seen as early as Week 1. ZORYVE cream was very well-tolerated. The incidence of Treatment Emergent Adverse Events was low and similar in both active treatment and vehicle arms. The most frequent adverse events in the ZORYVE cream arm included upper respiratory tract infection, diarrhea, and vomiting. All individual AEs occurred in less than4.1% of patients. Safety and tolerability results were consistent with previous trials of ZORYVE cream 0.15% in patients aged greater than or equal to6 years with AD.

08:23 EST Allarity to begin enrollments for Phase 2 protocol to advance stenoparib - Allarity Therapeutics announced that the new protocol for its Phase 2 clinical trial of stenoparib in ovarian cancer is set to begin and will be expected to provide critical data by end of summer 2026 for a pivotal registration trial. The new protocol design was constructed following in-depth review of the Company's ongoing Phase 2 clinical data in collaboration with key ovarian cancer thought leaders and treating physicians, including the gynecologic oncologists who have been treating patients with stenoparib in the ongoing phase 2 study. This comprehensive review revealed compelling evidence for stenoparib's durable clinical benefit in platinum-resistant, advanced ovarian cancer patients, including a complete, confirmed response as well as two patients remaining on therapy without progression for more than 17 months. The protocol reflects the feedback of these gynecologic oncology experts as well as input from the FDA. The protocol has now also been approved by the Institutional Review Board of the first trial sites, paving the way for the trial to begin patient enrollment immediately. Anticipating IRB approval, to advance stenoparib, Allarity recently completed a new drug manufacturing campaign and has readied finished drug product for delivery to sites to expedite patient enrollment. This new protocol was designed expressly to enrich the understanding of clinical benefit in a well-defined ovarian cancer patient population with significant unmet medical need. In addition to further deepening the clinical experience for stenoparib, this trial will allow for the evaluation of the impact of stenoparib on the Wnt pathway, a critical cellular signaling pathway implicated in advanced ovarian cancer and multiple other malignancies, including colon cancer. A deeper understanding of stenoparib's role in modulating the Wnt pathway would further differentiate stenoparib in the $9B+ PARP inhibitor market. The ongoing Phase 2 study was the first stenoparib study to assess twice-daily dosing and showed clear evidence for clinical benefit. The new protocol will build upon this clinical experience with the current dose while introducing an additional dose level to assess whether clinical benefit can be further enhanced. Ultimately, this trial will allow Allarity to address the FDA's recent "Project Optimus" guidelines and will set the stage for pivotal registration studies. Allarity expects to pursue multiple advantaged regulatory pathways to expedite approval in the first half of 2025.

08:21 EST Celularity enters master services collaboration agreement with BlueSphere Bio - Celularity has entered into a Master Services Collaboration Agreement with BlueSphere Bio, covering manufacturing activities for certain BSB cell therapy products. This collaboration is the second of its kind for Celularity and demonstrates the Company's ability to leverage its world class cGMP manufacturing infrastructure and deep expertise to attract clients like BSB, who are seeking differentiated alternatives to manufacture their therapeutic products in an ever-changing landscape. This collaboration further evidences the revenue generating potential of Celularity's assets. The Collaboration Agreement will initially focus on the production of BSB's novel T cell receptor T cell therapies using the technical and manufacturing capabilities at Celularity's Florham Park, NJ, cGMP-ready facility. This collaboration will extend to all aspects of cell therapy manufacturing including Chemistry, Manufacturing and Controls, Quality Assurance and Quality Control. As part of this Collaboration, Celularity will dedicate staff and a small portion of its 37,000 square foot commercial manufacturing footprint. In coordination with Celularity management, BSB and its team will have oversight over production of its second cell therapy product for the treatment of Acute Myelogenous Leukemia both in the U.S. and abroad.

08:19 EST Manulife Financial announces automatic share repurchase plan - Manulife Financial announced that it has entered into an automatic share repurchase plan under which its designated broker will repurchase Manulife's common shares pursuant to its previously announced normal course issuer bid. The actual number of common shares purchased under the automatic plan, the timing of such purchases and the price at which common shares are purchased will depend upon future market conditions. The automatic plan, which was pre-cleared by the TSX, provides for the potential repurchase of common shares at any time, including when Manulife ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules, or otherwise.

08:17 EST Robinhood announces closure of SEC investigation into Robinhood Crypto - The SEC has officially closed its investigation into Robinhood Crypto. Tthe SEC's Enforcement Division advised RHC in a letter that it had concluded its investigation and did not intend to move forward with an enforcement action. This follows the SEC's May 2024 Wells Notice to RHC. "We applaud the staff's decision to close this investigation with no action," said Dan Gallagher, chief legal, compliance and corporate affairs officer, Robinhood. "Let me be crystal clear-this investigation never should have been opened. Robinhood Crypto always has and will always respect federal securities laws and never allowed transactions in securities. As we explained to the SEC, any case against Robinhood Crypto would have failed. We appreciate the formal closing of this investigation, and we are happy to see a return to the rule of law and commitment to fairness at the SEC."

08:16 EST Alcon a launches OTC eye drop SYSTANE PRO preservative-free PF - Alcon announced the U.S. launch of SYSTANE PRO Preservative-Free PF as the latest over-the-counter eye drop in the company's dry eye portfolio. SYSTANE PRO PF is the longest lasting eye drop in the SYSTANE portfolio with a unique triple action, preservative-free formula for the temporary relief of burning and irritation due to dryness of the eye. "We are proud to introduce SYSTANE PRO PF, the first and only multi-dose preservative-free triple action formula with hyaluronate, nano-sized lipids and HP-Guar that support the active ingredient giving patients long-lasting relief from the symptoms of dry eye," said Terry Kim, MD, Chief Medical Officer and Head of Global Medical Safety, Alcon. "This is another example of how Alcon is bringing innovation to the SYSTANE portfolio to address the needs of dry eye patients." The launch begins in the U.S. this month and will extend to additional markets in 2026. SYSTANE PRO PF will be featured at the SECO International meeting this week in Atlanta, Georgia.

08:14 EST Inhibikase appoints Chris Cabell as president, head of R&D, John Adams as CSO - Inhibikase Therapeutics announced the appointment of two pharma industry executives to its senior leadership team. Chris Cabell, M.D., former CMO of Arena Pharmaceuticals and CEO of CorHepta Pharmaceuticals, has been appointed as President and Head of Research & Development. Additionally, CorHepta co-founder and former Head of Research at Arena Pharmaceuticals, John Adams, Ph.D. has been appointed Chief Scientific Officer. Additionally, Vince Aurentz will join Inhibikase Board of Directors He served as Executive Vice President and Chief Business Officer at Arena Pharmaceuticals.

08:12 EST Steel Dynamics increases quarterly cash dividend 9% to 50c per share - Steel Dynamics declared a Q1 cash dividend of 50c per common share, representing a 9% increase over the company's 2024 quarterly rate. The dividend is payable to shareholders of record at the close of business on March 31 and is payable on or about April 11.

08:11 EST Singular Genomics highlights G4X milestones at AGBT - Singular Genomics announced key development milestones for its G4X Spatial Sequencer at the Advances in Genome Biology and Technology conference in Marco Island, Florida.The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. Singular plans to expand its early access program to a few more sites in Q2. Meanwhile, pre-orders for the G4X are now open, and initial shipments are on track for June 2025. Researchers wishing to start generating multiomic data can use Singular's technology access services in the meantime. At AGBT, Singular Genomics presented data demonstrating the G4X platform's robust integrated multiomic performance. Immune-oncology-focused lung, kidney, colon, and breast panels showed high sensitivity, specificity, and reproducibility in FFPE samples, providing comprehensive spatial insights into cancerous and healthy tissues. Building on these data, Singular showcased advanced 3D multi-omic reconstruction and niche detection from 10 serial renal cell carcinoma FFPE sections, over 6.2 million cells, and 438 million transcripts-all from a single G4X flow cell.

08:10 EST SaverOne 2014 granted U.S. patent further expanding IP portfolio - SaverOne 2014 announced the award by the United States Patent and Trademark Office of a new patent. The patent, bearing the number 12,231,899 and issued on February 18, 2025, is entitled "System and method for managing access to software applications on a mobile communication device via a phone location unit." This newly issued patent complements SaverOne's comprehensive in-vehicle safety solution by controlling and limiting the use of phone applications by the driver while driving. It ensures that the driver can access only allowed applications, as per the corporate safety policy, such as phone or navigation, while all others remain inaccessible. This is done using wireless communication between SaverOne's Phone Location Unit in the vehicle and its mobile application on the driver's phone. Under U.S. law, the patent term is 20 years from the application's effective filing date

08:08 EST Rezolve AI launches bitcoin treasury - Rezolve Ai unveiled a $1B Bitcoin treasury programme, kickstarting with an initial $100M investment. The company said, "This visionary move underscores Rezolve Ai's unwavering commitment to revolutionizing global commerce by seamlessly integrating artificial intelligence, blockchain technology, and cryptocurrency. The Bitcoin treasury is not just a financial strategy - it's a game-changing initiative designed to directly support the planned launch of Rezolve Ai's crypto payment platform, the recently announced initiative with Tether - the largest company in the digital asset industry. By establishing a robust Bitcoin reserve, Rezolve Ai is positioning itself to lead the charge in mainstream crypto adoption, enabling millions of consumers and retailers to transact effortlessly with Bitcoin, Tether, and other digital assets."

08:07 EST reAlpha acquires GTG Financial, terms not disclosed - reAlpha Tech announced the acquisition of GTG Financial, a mortgage brokerage company founded by Glenn Groves. GTG Financial is licensed to operate in seven U.S. states, including California, which will expand reAlpha's geographic footprint to a total of 28 U.S. states and strengthen its operational capacity. The company said, "The acquisition of GTG Financial marks another step in reAlpha's strategy to further enhance its mortgage operations and provide a more seamless home financing experience within the reAlpha platform, its AI-powered real estate platform. By incorporating GTG Financial's experience in the real estate industry and its added workforce of loan officers, reAlpha anticipates that it will be able to bolster its overall operational capacity, expand its loan processing capabilities and offer mortgage lending and refinancing services to homebuyers more efficiently." GTG Financial will retain its brand identity under the leadership of its founder, Glenn Groves, while leveraging reAlpha's resources and generative AI platform, which is expected to enhance loan processing efficiency and support a more seamless home financing experience.

08:07 EST Summit Therapeutics announces clinical trial collaboration with Pfizer - Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF bispecific antibody, in combination with several of Pfizer's antibody drug conjugates across multiple solid tumor settings. "The goal of the collaboration is to evaluate ivonescimab, in combination with several unique Pfizer ADCs across multiple solid tumor settings to accelerate the advancement of potentially landscape-changing combinations, which seek to improve the standards of care for patients facing serious unmet needs. Each study intends to evaluate ivonescimab plus one of Pfizer's vedotin ADCs in individual, distinct solid tumor settings to determine the safety profile and potential anti-tumor activity of the combinations," the companies said in a statement. Under the terms of the agreement, Summit will provide ivonescimab for use in the proposed studies, and Pfizer will be responsible for conducting the operations of the studies. The studies will be overseen by both Summit and Pfizer. Both parties retain their respective rights to their products. The studies combining ivonescimab with Pfizer's vedotin ADCs are planned to begin in the middle of this year. Further details on the clinical trials will be announced at a later date.

08:06 EST Acurx's ibezapolstat shows efficacy in CDI treatment - Acurx announced the results of a study and its publication in the Journal of Antimicrobial Agents and Chemotherapeutics. During clinical trials with ibezapolstat, or IBZ, a narrower than expected spectrum of activity was observed that included increased proportion of certain key microbiota of the Bacillota phylum known to confer health benefits. The purpose of this study was to utilize in silico approaches to better interpret the narrower than expected IBZ spectrum of activity observed in human trials. IBZ susceptibility to human commensal microbiota was predicted using genomic analysis and PolC phylogenetic tree construction in relation to C. difficile and commensal low G + C bacteria. An amino acid phylogenetic tree identified certain residues that were phylogenetically variant in Lachnospiraceae, Oscillospiraceae, and Erysipelotrichales but conserved in C. difficile. The major finding of this study was that the predicted interactions between IBZ and pol IIIC is conserved across the majority of the Bacillota phylum except for Lachnospiraceae and Oscillospiraceae, and Erysipelotrichales, taxa that were not killed or regrown in IBZ-treated subjects while on therapy. Preparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDI. IBZ has previously been granted FDA QIDP and Fast-Track Designation and has received Small and Medium-sized Enterprise designation by the EMA.

08:05 EST Apollo Global to acquire Bridge Investment Group in $1.5B all-stock transaction - Apollo (APO) and Bridge Investment Group Holdings (BRDG) have entered into a definitive agreement for Apollo to acquire Bridge in an all-stock transaction with an equity value of approximately $1.5 billion. Founded in 2009, Bridge is an established leader in residential and industrial real estate as well as other specialized real estate asset classes. Led by an experienced senior leadership team and over 300 dedicated investment professionals with significant real estate investment and operating expertise, Bridge's forward-integrated model, nationwide operating platform and data-driven approach have fostered organic growth and consistently produced desirable outcomes across asset classes. Bridge will provide Apollo with immediate scale to its real estate equity platform and enhance Apollo's origination capabilities in both real estate equity and credit, which is expected to benefit Apollo's growing suite of hybrid and real estate product offerings. Bridge manages approximately $50 billion of high-quality AUM in real estate products targeting both institutional and wealth clients and is expected to be highly synergistic with Apollo's existing real estate equity strategies and leading real estate credit platform. The transaction is expected to be immediately accretive to Apollo's fee-related earnings upon closing. Under the terms of the transaction, Bridge stockholders and Bridge OpCo unitholders will receive, at closing, 0.07081 shares of Apollo stock for each share of Bridge Class A common stock and each Bridge OpCo Class A common unit, respectively, valued by the parties at $11.50 per each share of Bridge Class A common stock and Bridge OpCo Class A common unit, respectively. Upon the closing of the transaction, Bridge will operate as a standalone platform within Apollo's asset management business, retaining its existing brand, management team and dedicated capital formation team. Bob Morse will become an Apollo Partner and lead Apollo's real estate equity franchise. A special committee of independent directors for Bridge, advised by its own independent legal and financial advisors, reviewed, negotiated and unanimously recommended approval of the merger agreement by the Bridge Board of Directors, determining that it was in the best interests of Bridge and its stockholders not affiliated with Bridge management and directors. Acting upon the recommendation of the Special Committee, the Bridge Board of Directors approved the merger agreement. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions for transactions of this nature, including approval by a majority of the Class A common stock and Class B common stock of Bridge, voting together and the receipt of regulatory approvals. Certain members of Bridge management and their affiliates, collectively owning approximately 51.4% of the outstanding voting power of the Class A common stock and Class B common stock of Bridge, have entered into voting agreements in connection with the transaction and have agreed to vote in favor of the transaction in accordance with the terms therein. Subject to and upon completion of the transaction, shares of Bridge common stock will no longer be listed on the New York Stock Exchange and Bridge will become a privately held company.

08:02 EST Fresenius Medical divesting select laboratory assets to Quest Diagnostics - Fresenius Medical (FMS) and Quest Diagnostics (DGX) announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a provider of renal-specific laboratory testing services in the U.S. In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the U.S. By acquiring select laboratory assets from FME, Quest will add dialysis-related water testing, a new capability, to Quest's comprehensive portfolio. Financial terms were not disclosed. The acquisition is expected to close in the second half of 2025, pending customary state regulatory reviews. The transition of services is expected to be complete by early 2026.

07:48 EST Vision Marine files patent application for Outboard Power Control Unit - Vision Marine Technologies announces the filing of a new patent application for the Outboard Power Control Unit designed for Electric Marine Vessels. The patent application reinforces Vision Marine Technologies' role in advancing electric marine propulsion technology. The newly developed Outboard PCU autonomously manages propulsion parameters and cooling operations, delivering enhanced efficiency and reliability. Leveraging a dual-CAN bus architecture, the PCU promotes seamless communication with both internal sensors and actuators within the outboard engine housing and external vessel control units. This architecture enables real-time autonomous control of the electric motor, increasing performance while maintaining robust safety protocols and scalability.

07:44 EST Mako Mining receives conditional approval for Moss Mine acquisition - Mako Mining provide an update on Mako's proposed acquisition of the Moss Mine in Arizona, through the acquisition of 100% of the issued and outstanding common shares of EG Acquisition from investment funds controlled by Mako's controlling shareholder, Wexford Capital. Mako is pleased to announce that it has received the conditional approval of the TSX Venture Exchange for the Acquisition. Completion of the Acquisition remains subject to Mako satisfying all regulatory requirements and receiving the final approval of the TSXV. Mako is concurrently working on finalizing a definitive share purchase agreement with the Sellers in connection with the Acquisition. EGA took over full operational control of the Moss Mine on December 31st, 2024, and has a services contract with Mako's operating team who has been assisting EGA. Since that time, consumable inventories have been replenished, critical maintenance has been completed, and a scope of work has been issued to mining contractors to restart mining operations within the next five weeks. Since January 2025, gold and silver sales from the Moss Mine have continued unabated with 832 oz. gold and 5,607 oz. silver shipped with an estimated value of $2.6 million. This significantly exceeds a $1.6 million cash infusion made by EGA into the operating company at the beginning of January for critical maintenance and repairs. While the previously announced non-binding term sheet for the Acquisition contemplates a purchase price of between $4.9 million and $6.4 million all the net cashflow derived from gold and silver sales since December 31st, 2024 will accrue to the benefit of Mako under the proposed terms of the Acquisition. In addition, Mako is expected to receive approximately $1.5 million in cash collateral from Trisura Guarantee Insurance Company in connection with the renegotiation of certain environmental reclamation bonds at the Moss Mine, which will have the impact of lowering the effective purchase price of the Acquisition by such amount.

07:39 EST Microchip launches MPLAB XC Unified Compiler Licenses - Microchip Technology has launched MPLAB XC Unified Compiler Licenses for its MPLAB XC8, XC16, XC-DSC and XC32 C compilers. This unified approach addresses the financial strain and administrative burden of purchasing and managing separate software access models for each compiler. Microchip's solution consolidates the necessary licenses to reduce overhead and provide greater flexibility, scalability and ease of use.

07:39 EST Plus Therapeutics appoints Russell Bradley as president, CNSide - Plus Therapeutics announced that is has appointed Russell Bradley as the President and General Manager of its wholly-owned subsidiary, CNSide Diagnostics. Furthermore, Plus has also appointed Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley to the CNSide Board of Directors, and Dr. Jonathan Stein has been named CNSide Medical Director. Bradley brings over 30 years of leadership experience in diagnostics and life sciences, having held senior executive roles at Abbott Laboratories, Luminex Corporation, and Beckman Coulter. Stein served as Medical Director at Gene By Gene and as a Research Investigator at M.D. Anderson Cancer Center.

07:35 EST Houston American Energy enters agreement to acquire Abundia Global Impact Group - Houston American Energy has entered into a definitive agreement to acquire Abundia Global Impact Group, a company specializing in converting waste into high value fuels and chemicals. The acquisition supports HUSA's strategy to diversify its portfolio, expand its global footprint and execute its comprehensive strategy aimed at driving shareholder value through innovation in the renewable energy sector. The agreement is subject to HUSA shareholder approval and standard closing conditions. Under the terms of the agreement, HUSA will acquire 100% of AGIG's issued and outstanding units from AGIG's members and HUSA will issue to AGIG's members a number of shares of HUSA common stock which shall equal 94% of HUSA's aggregate issued and outstanding common stock at the time of the Closing. AGIG is preparing to build its first advanced plastic recycling facility in Cedar Port, Texas. The facility represents the first phase of a structured, capital-efficient growth plan aimed at scaling and deploying AGIG's suite of technologies for producing renewable fuels and chemicals from waste. AGIG's Cedar Port facility will serve as the hub for its five-year development plan in the US. This facility will be designed to scale production capacity while maintaining capital discipline. The company's proven upgrading processes, strategic technology partnerships, and established industry relationships are expected to provide a clear path to commercialization. HUSA and AGIG will continue working toward a structured integration and execution plan, with additional updates expected in the coming months as the acquisition advances toward closing and AGIG further develops its business. HUSA expects to close on the AGIG acquisition early in the second quarter.

07:34 EST Connexa Sports signs content creation agreement with TikTok - Connexa Sports Technologies' Yuanyu Enterprise Management has signed a Multi-Channel Network agency services agreement to create and sell content to TikTok as part of its new vertical centered on social networking applications. Under this agreement, YYEM will procure the production of content to be live-streamed or served as videos to TikTok's multitude of users in the Middle East and North Africa. This is expected to include engaging broadcasts across various categories, such as sports, gaming, and lifestyle topics, produced by popular Twitch hosts and other influencers within the network that YYEM is developing. The company said, "We anticipate that YYEM's new vertical will also include live-streaming, voice chat rooms, gaming, and influencer-driven user-generated content. The fees generated by the arrangement with TikTok will depend on the rate of conversion by TikTok end-users."

07:30 EST Allegro MicroSystems appoints Mike Doogue as CEO - Allegro MicroSystems announced the appointment of Mike Doogue as President and CEO and as a member of the Board. Doogue's ascension to CEO comes after 27 years of rising through the leadership ranks at Allegro, during which time he enabled many of Allegro's disruptive technologies, originally as an engineer and later as a business leader. Immediately prior to this promotion, Mr. Doogue served as Allegro's Executive Vice President and its first CTO. Doogue succeeds Vineet Nargolwala, who is stepping down as President and CEO and as a member of the Board.

07:28 EST PyroGenesis signs C$2.4M contract with Norsk Hydro - PyroGenesis announces that it has signed a EUR 1.63M, or C$2.4M, contract with aluminium and renewable energy company Norsk Hydro as part of its stated plan to test plasma technology as one of the ways to replace fossil fuel with renewable alternatives in its aluminum casthouses.

07:25 EST Xortx Therapeutics commences gout program NDA discussions with FDA - XORTX Therapeutics has submitted a Type C meeting request with the US Food and Drug Administration regarding the Company's XRx-026 program for the treatment of gout. Development of XORLO 1, the Company's proprietary drug formulation of oxypurinol, has advanced to the point where a Type C meeting and discussion with the FDA is warranted. The purpose of this meeting is to review the XRx-026 program and its readiness for submission of a New Drug Application to gain marketing approval for XORLO in the US using the FDA's 505(b)2 development pathway. The Company will provide updates on the progress of the XRx-026 gout program when additional information is available.

07:22 EST Atea Pharmaceuticals appoints Arthur Kirsch to board of directors - Atea Pharmaceuticals announced the appointment of Arthur S. Kirsch to the Company's Board of Directors. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group.

07:20 EST Americas Gold and Silver provides update on ongoing work at Galena - Americas Gold and Silver Corporation is pleased to provide an update on its ongoing work programs at the Galena Complex or Galena, following the closing of the Galena consolidation and recapitalization transaction closed on December 19. Significant progress has been made in identifying opportunities and initiating action as part of the Company's technical review and optimization work to ensure that the Galena Complex reaches its full production potential, underscoring the Company's ongoing commitment to operational efficiency, safety, production growth, and maximizing value from existing assets. This progress includes initial work on the #3 shaft, a trade off study currently underway at the mine and the ordering of new mining equipment to boost productivity underground. The Company is also pleased to release new drilling results that continue to demonstrate the geologic prospectivity of the deposit and identify new veins that could be brought into production with further drilling. Lastly, as a result of an initial review of byproduct metallurgical performance, the Company has also initiated further test work to evaluate the potential to maximize recoveries of copper and antimony.Paul Huet, CEO of Americas Gold and Silver, commented: "The first two months of review and optimization work undertaken at the Galena Complex have been remarkably productive. I have been very impressed by the energized workforce and the tremendous potential of our primary silver asset. In my 35 years of mining, We have also ordered five new pieces of equipment, with initial deliveries this quarter. On the exploration front, the Galena Complex continues to demonstrate its exceptional exploration potential under the new leadership team. The discovery of the 049 Vein, along with the discovery of the new 181 & 182 Veins and the 368 Vein, reaffirms our ...confidence in the long-term sustainability of this asset. Finally, our review of metallurgical opportunities identified during our due diligence has led to immediate action with new sampling programs underway to optimize our concentrate by product potential by capturing previously untapped metal value. As we move forward with these exciting programs, we remain committed to improving the productivity of the operation through a safety-focused approach. We look forward to sharing further progress on all of our initiatives in the coming months."

07:18 EST FiscalNote to divest Oxford Analytica, Dragonfly to Dow Jones for $40M - FiscalNote (NOTE) announced it has entered into a definitive agreement to divest two portfolio companies within its global intelligence business, Oxford Analytica and Dragonfly, to Dow Jones, a news and information provider and division of News Corp. (NWSA), for total consideration of $40M. The transaction is expected to close in Q1, subject to receipt of antitrust clearance in Austria and other customary closing conditions. The transaction is not subject to any financing condition. Oxford Analytica, acquired by FiscalNote in February 2021, produces geopolitical analysis and provides advisory services to help customers understand and respond to political, economic, and societal risks. Dragonfly, acquired by FiscalNote in January 2023, provides forward-looking global security intelligence and data that customers utilize to keep operations, personnel, and assets safe. The Oxford Analytica and Dragonfly businesses have offered their products independently of FiscalNote's core products. Oxford Analytica and Dragonfly are each primarily based in the United Kingdom.

07:16 EST OTC Markets Group welcomes Anaergia to OTCQX - OTC Markets Group announced Anaergia has qualified to trade on the OTCQX Best Market. Anaergia upgraded to OTCQX from the Pink market.

07:15 EST Volato makes step in exploration of aviation-integrated cryptocurrency mining - Volato Group announced that it has begun Bitcoin mining operations, marking an early but significant step in its broader exploration of aviation-integrated cryptocurrency mining. With this milestone, Volato expects to hold Bitcoin on its balance sheet for the first time in Q1 2025..."While we are in the early stages and have not yet begun mining in the air, launching Bitcoin mining operations on the ground is an important step in refining our approach," said Matt Liotta, CEO of Volato. "We believe the Citation CJ is the right platform to start with as we explore how aviation and cryptocurrency mining intersect." As Bitcoin miners face rising energy costs and regulatory pressures, interest is growing in alternative mining models. While Volato's mining technology remains under development, early discussions with large-scale miners have confirmed genuine curiosity about aviation's role in the industry's future. Volato will provide further updates as development progresses.

07:12 EST FDA gives Glaukos 'Day 74' notice for Epioxa NDA to treat keratoconus - Glaukos announced it has received the "Day 74" notification from the U.S. Food and Drug Administration FDA acknowledging the previously submitted New Drug Application NDA for Epioxa Epi-on , its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, is sufficiently complete to permit a substantive Epi-on. The Prescription Drug User Fee Act PDUFA goal date for the completion of the FDA's review of the Epioxa NDA is set for October 20. This date reflects a standard 10-month review period, which is consistent with the company's expectations. "The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye," said Thomas Burns, Glaukos chairman and chief executive officer. ...The NDA submission includes data from two Phase 3 pivotal trials of Epioxa, which both successfully achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles. ...Conventional keratoconus treatments such as eyeglasses or contact lenses address symptoms but Glaukos' first-generation iLink therapy, known as Photrexa or Epi-off, is the first and only FDA-approved therapy that has been shown to slow or halt disease progression Epioxa would be the first FDA-approved, non-invasive corneal cross-linking therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye.

07:10 EST Volaris sees Q1 ASM growth 7% year-over-year - Sees TRASM 8c; CASM ex fuel 5.5c-5.6c; EBITDAR margin 28%-29%.

07:09 EST Volaris sees FY25 ASM growth 13% year-over-year - Sees EBITDAR margin 34%-36%. Sees capex $250M.

07:07 EST Siyata Mobile expands istribution in new agreement with IP Access International - Siyata Mobile announced a new distribution agreement with IP Access International, a provider of communication solutions for organizations operating in challenging environments. Through this partnership, IP Access International will offer Siyata's SD7 PoC devices and accessories to its customer base, which includes fire departments, mining operations, oil and energy companies, utilities, and other industries that require mission-critical communication solutions in remote areas. Siyata's SD7 devices will integrate with IP Access International's SuperGIG solution, combining major cellular carriers, OneWeb and Starlink LEO constellations, and a GEO satellite backup into a single network.

07:05 EST Nektar announces clinical trial agreement to evaluate Rezpegaldesleukin - Nektar Therapeutics announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus. Rezpegaldesleukin is a novel agonistic T regulatory cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D. Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

07:03 EST Dow Jones to acquire Dragonfly Intelligence, Oxford Analytica from FiscalNote - Dow Jones announced it has agreed to acquire Dragonfly Intelligence, a geopolitical and security intelligence provider, and Oxford Analytica, a provider of geopolitical intelligence advisory services from FiscalNote Holdings (NOTE) for $40M. The acquisition is expected to close in the first quarter of 2025 and is subject to regulatory approval in Austria and customary closing conditions. Dow Jones's parent company, News Corp (NWS), expects to receive a $4M tax benefit in connection with the transaction.

07:00 EST FDA accepts Bristol Myers' sBLA for Opdivo plus Yervoy - Bristol Myers Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a potential first-line treatment option for adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer. The FDA granted the application Breakthrough Therapy Designation and Priority Review status and assigned a Prescription Drug User Fee Act goal date of June 23, 2025.

06:52 EST Wallbox receives $10M investment - Wallbox announced an investment of approximately $10M. Investors include Inversiones Financieras Perseo, - Iberdrola's subsidiary -, Orilla Asset Management, and Enric Asuncion, CEO and Co-Founder. This investment strengthens Wallbox's balance sheet and provides the necessary capital to support the worldwide sales of its EV chargers.

06:47 EST Brown & Brown appoints Stephen Hearn as COO - Brown & Brown appointed Stephen Hearn, an insurance industry veteran who joined the company's board of directors in August 2024, as EVP and COO. In connection with this appointment, Hearn has resigned from the company's board of directors and will join the company's operating committee. Hearn began his insurance career in 1989, most recently holding roles with The Ardonagh Group. During his time with The Ardonagh Group, he served as CEO of Ardonagh Specialty Holdings; as CEO of Ardonagh Capital Solutions and as CEO of Inver Re, The Ardonagh Group's dedicated reinsurance broking unit. He also served as a director of Ardonagh International from May 2023 to July 2024. Previously, he served as CEO of Corant Global, a subsidiary of BGC Partners and as CEO of Ed Broking Group. Prior to that, he held senior leadership positions with Hilb, Rogal & Hobbs; Glencairn; Marsh Affinity Europe & Middle East; Marsh Affinity UK and Sedgwick Affinity Group Services.

06:37 EST Cycurion expands cybersecurity partnership with public health associations - Cycurion has announced an expansion of its partnership with a major national public health association, bringing its Managed Security Services Platform to several thousand member organizations across the country. This expansion builds on Cycurion's cybersecurity engagement with the association itself, where its solutions were implemented to protect critical systems and infrastructure. The association has now partnered with Cycurion to extend these protections to its members. Cycurion's proprietary ARx Platform is a cybersecurity solution leveraging machine learning and AI technologies developed over the past four years which provides real-time threat detection, automated response, and compliance management. This expanded partnership represents a cybersecurity initiative over the next 24 to 36 months.

06:18 EST Apple to double its U.S. Advanced Manufacturing Fund - Apple is doubling its U.S. Advanced Manufacturing Fund, which was created in 2017 to support world-class innovation and high-skilled manufacturing jobs across America. The growing commitment will increase the fund from $5B to $10B, focused on promoting advanced manufacturing and skills development throughout the country. The fund's expansion includes a multibillion-dollar commitment from Apple to produce advanced silicon in TSMC's Fab 21 facility in Arizona. Apple is the largest customer at this state-of-the-art facility, which employs more than 2,000 workers to manufacture the chips in the United States. Mass production of Apple chips began last month.

06:15 EST Jakks Pacific's Disguise and The Pokemon Company sign contract extension - Disguise, the globally recognized costume division of Jakks Pacific, announced an expansion of its long-standing agreement with The Pokemon Company International through a multi-year contract extension. This agreement grants Disguise distribution rights in North America as well as EMEA, ANZ and select parts of LATAM, reinforcing its position as a leader in the costume industry and allowing them to continue to design, develop, and manufacture Pokemon-inspired costumes and accessories now for fans domestically and internationally.

06:13 EST Revelation Biosciences receives continued Nasdaq listing approval - Revelation Biosciences announced the Nasdaq Stock Market formally notified the company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing.

06:11 EST GSK commences share buyback program - GSK plc announces the commencement of its share buyback program, as announced in its 2024 full year results announcement published on 5 February 2025. The Program will return an additional GBP 2B of capital to shareholders and is expected to be completed within 18 months of the FY24 Results Date. The Program will commence today with an initial tranche of up to GBP 0.7B. GSK has entered into a non-discretionary agreement with Citigroup Global Markets Limited, enabling GSK to buy back ordinary shares of 31 pence each in GSK with an aggregate value of up to GBP 0.7B. Purchases of Ordinary Shares under the First Tranche are expected to commence on 24 February 2025 and to be completed by 13 June 2025. The purpose of the Program is to return excess capital to shareholders and reduce the share capital of the company, and it is expected that the implementation of the Program will enhance earnings per share. Ordinary Shares purchased under the First Tranche will be held as Treasury shares. Citi will make trading decisions in relation to the First Tranche independently of GSK with regard to the timing of purchases. Any purchase of Ordinary Shares by Citi contemplated by this announcement will be carried out on the London Stock Exchange and/or Cboe Europe Limited through the BXE and CXE order books. Any purchases of Ordinary Shares by GSK from Citi under the First Tranche will be carried out on the London Stock Exchange.

06:09 EST Fresh Del Monte raises quarterly dividend to 30c, announces $150M share buyback - Fresh Del Monte Produce announced that its Board of Directors has approved a $150M share repurchase program, reinforcing its balanced capital allocation strategy. Additionally, the Board has announced an increase in the quarterly dividend from 25c to 30c. The next quarterly dividend will be paid on March 28 to shareholders of record on March 10. The new plan has no time deadline and will continue until otherwise modified or terminated by the company's Board at any time in its sole discretion

06:08 EST Sigma Lithium provides update on construction of second Greentech plant - Sigma Lithium provided an update on its advancement of the construction of its second Greentech industrial plant to double its production capacity of lithium oxide concentrate. Sigma Lithium is on track to double its production capacity in 2025, with commissioning expected to begin in Q4. To date, the company has completed 100% of the foundation earthworks for the second Greentech industrial plant, staying on schedule and within budget. The first cement has been poured, and construction has advanced to civil works, including the completion of water drainage infrastructure for the second industrial site. In addition, detailed engineering with technical specifications has been completed for certain key equipment items with long manufacturing lead times. Procurement and contractual negotiations have been completed, and orders for these items are expected to be placed within the current quarter. Initial deliveries of the plant's equipment are expected to commence in June 2025, followed by the assembly of mechanical structures.Currently, there are 100 people working on the expansion project, with plans to increase the workforce to 1,000 at peak construction. The company has also accelerated its homecoming program with the creation of a training center for heavy machinery operators in one of the neighboring communities. Sigma Lithium has secured a $100M development bank credit line from BNDES to fully fund the construction. The company decided to continue advancing its construction, despite the current lithium cycle, due to low capital expenditure intensity. This efficiency is driven in part by existing infrastructure, which supports the additional Greentech Industrial Plant and enables us to fast-track construction timelines while controlling costs.

06:01 EST Apple to spend over $500B in U.S. over next four years - Apple announced its largest-ever spend commitment, with plans to spend and invest more than $500 billion in the U.S. over the next four years. This new pledge builds on Apple's long history of investing in American innovation and advanced high-skilled manufacturing, and will support a wide range of initiatives that focus on artificial intelligence, silicon engineering, and skills development for students and workers across the country. "We are bullish on the future of American innovation, and we're proud to build on our long-standing U.S. investments with this $500 billion commitment to our country's future," said Tim Cook, Apple's CEO. "From doubling our Advanced Manufacturing Fund, to building advanced technology in Texas, we're thrilled to expand our support for American manufacturing. And we'll keep working with people and companies across this country to help write an extraordinary new chapter in the history of American innovation." As part of this package of U.S. investments, Apple and partners will open a new advanced manufacturing facility in Houston to produce servers that support Apple Intelligence(TM), the personal intelligence system that helps users write, express themselves, and get things done. Apple will also double its U.S. Advanced Manufacturing Fund, create an academy in Michigan to train the next generation of U.S. manufacturers, and grow its research and development investments in the U.S. to support cutting-edge fields like silicon engineering. The $500 billion commitment includes Apple's work with thousands of suppliers across all 50 states, direct employment, Apple Intelligence infrastructure and data centers, corporate facilities, and Apple TV+(R) productions in 20 states. Apple remains one of the largest U.S. taxpayers, having paid more than $75 billion in U.S. taxes over the past five years, including $19 billion in 2024 alone. Apple supports more than 2.9 million jobs across the country through direct employment, work with U.S.-based suppliers and manufacturers, and developer jobs in the thriving iOS app economy.

05:25 EST Just Eat Takeaway.com to be acquired by Prosus N.V. for EUR 20.30 per share - Prosus N.V. announced it has reached a conditional agreement to acquire Just Eat Takeaway.com to create the fourth largest food delivery group globally. Prosus intends to acquire Just Eat Takeaway.com's entire issued share capital for EUR 20.30 per share via a recommended all-cash public offer on the Amsterdam exchange. This represents a 49% premium to the three-month VWAP as of February 21 and a 22% premium to Just Eat Takeaway.com's highest share price over the last three months.

05:20 EST Sandoz launches Pyzchiva in the U.S. - Sandoz announced the launch of Pyzchiva in the U.S. The medicine is now commercially available to patients across the U.S.

05:12 EST RTX awarded multi-million-dollar contract by Danish Defence Armed Forces - RTX was awarded an additional multi-million-dollar contract by the Danish Defence Armed Forces for ELCAN Specter DR dual role sights. The NATO Support Procurement Support Agency is the contracting authority. The ELCAN Specter DR sight is a direct-view optic that provides close quarters and precision capability in a single sight. The Specter DR sight switches instantly between magnifications, providing the user with "both eyes open" target acquisition while boresight, eye relief and sight picture remain constant.

05:08 EST Sophia Genetics announces adoption of MSK-Access - Sophia Genetics announced a new milestone in the adoption of its cancer testing applications MSK-Access powered with Sophia DDM and MSK-Impact powered with Sophia DDM. Thirty-seven institutions have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.